This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Genzyme Honors Innovation In Gaucher Disease Research Through Its 2012 Gaucher Generation Program Awards

Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), today announced the recipients of the 2012 Gaucher Generation Program awards, an annual program in its fifth year that awards scientists and clinicians engaged in innovative Gaucher disease research.

Genzyme’s Gaucher Generation program provides funding to researchers throughout the world to stimulate and support the advancement of medical knowledge in Gaucher disease. An independent committee of international Gaucher disease experts reviewed the research proposals and selected the most meritorious applications. This year, two “New Investigator Awards” were given, with each recipient receiving $100,000 over two years, as well as one “Established Investigator Award” with an award of $150,000 over two years.

“The Gaucher Generation Program represents Genzyme’s ongoing commitment to enhance care and support of the global Gaucher community, with the ultimate goal of transforming the lives of patients,” said Genzyme’s Senior Vice President and Head of Rare Diseases, Rogerio Vivaldi, MD. “As world-renowned thought leaders, each of these recipients will make a meaningful contribution to further the understanding of Gaucher disease. Genzyme has been committed to serving the Gaucher community for over 20 years, and we are proud to support these award recipients in their important work.”

This year’s recipients are:

New Investigator Awards:
  • Gustavo Tiscornia, PhD, Assistant Professor in the Department of Biomedical Sciences and Medicine and Center for Molecular and Structural Biomedicine at the University of Algarve, Faro, Portugal. Dr. Tiscornia’s project is entitled “Development of an induced pluripotent stem cell model of neuronopathic Gaucher’s Disease for investigating mechanisms of pathogenesis and small molecule testing.” Dr. Tiscornia will focus on the use of stem cells to study Gaucher disease type 2, which involves the nervous system.
  • Elena Pavlova, MD, PhD, Addenbrooke’s Hospital, University of Cambridge, Cambridge, UK. In Dr. Pavlova’s project entitled, “Lymphoma in Gaucher disease – studies of causation and potential cure,” she will focus her efforts to better understand why patients with Gaucher disease have an increased risk of cancer.

Established Investigator Award:
  • Pramod K Mistry, MD, PhD, Professor of Pediatrics and Internal Medicine, Chief, Pediatric Hepatology, and Director, National Gaucher Disease Treatment Center at Yale University School of Medicine, New Haven, Conn., USA. Dr. Mistry’s project is entitled “Studies to delineate specific phenotypes of Gaucher disease and decipher respective biomarker signatures and genetic underpinnings.” Dr. Mistry will seek to better understand how genes impact clinical and biochemical manifestations in patients with Gaucher disease.

For the 2012 application year, an international committee of Gaucher disease experts scored the research proposals. Submissions were considered on the basis of scientific merit, adequacy of the experimental design, and feasibility of the proposed study. Higher consideration was given to proposals that had the potential for improving patient outcomes. The judges were blinded to the identity of the applicants until final decisions were made. More information on Genzyme’s Gaucher Generation Program, including previous recipients, can be found at:

About Genzyme, a Sanofi Company

Genzyme has pioneered the development and delivery of transformative therapies for patients affected by rare and debilitating diseases for over 30 years. We accomplish our goals through world-class research and with the compassion and commitment of our employees. With a focus on rare diseases and multiple sclerosis, we are dedicated to making a positive impact on the lives of the patients and families we serve. That goal guides and inspires us every day. Genzyme’s portfolio of transformative therapies, which are marketed in countries around the world, represents groundbreaking and life-saving advances in medicine. As a Sanofi company, Genzyme benefits from the reach and resources of one of the world’s largest pharmaceutical companies, with a shared commitment to improving the lives of patients. Learn more at

Genzyme ® is a registered trademark of Genzyme Corporation. All rights reserved.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.02 0.00%
FB $104.07 0.00%
GOOG $683.57 0.00%
TSLA $154.71 -12.00%
YHOO $27.97 0.00%


Chart of I:DJI
DOW 16,204.97 -211.61 -1.29%
S&P 500 1,880.05 -35.40 -1.85%
NASDAQ 4,363.1440 -146.4150 -3.25%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs